Ubiquitin linkage is critical in directing the cellular fate of a ubiquitinated protein. Although K48-linked polyubiquitination of p53 leads to its degradation, whether K48-independent ubiquitin linkages are involved in p53 activation remains unknown. Here, we show that FATS acts as a p53 activator by inhibiting Mdm2 binding to p53 and stimulating non-proteolytic polyubiquitination of p53. Knockdown of FATS impairs p53 stabilization and activation in response to DNA damage. Furthermore, the NH2-terminal domain of FATS is sufficient to exhibit ubiquitin ligase (E3) activity and assemble ubiquitin polymers through K11-, K29-and K63-linkages, independently of the ubiquitin-conjugating enzyme (E2). FATS promotes p53-dependent transcription of p21, leading to robust checkpoint response. The E3 activity of FATS is required for promoting p53 stability and activation in response to DNA damage. Our findings reveal K48-linkage-independent non-linear polyubiquitination of p53 as a new barcode for p53 activation.
INTRODUCTION
Ubiquitination is a central mechanism to modulate protein function, which is initiated by ubiquitin activation through the ubiquitin-activating enzyme (E1) in an ATP-dependent manner. 1 The covalent attachment of ubiquitin to other proteins occurs generally through E1-E2-E3 multi-enzyme cascades. E1 passes ubiquitin to E2, which is also linked to ubiquitin through a thioester bond. E3 can itself form a thioester bond with ubiquitin (HECT-domain E3s) before substrate attachment or can function as a bridge between an activated E2 and its substrate (RING-domain E3s). Ubiquitin is usually attached to the e-amino group of Lys residues in substrates, which can recruit binding partners and modulate protein activities. 2 Ubiquitin linkages are responsible for functional consequences of ubiquitination, for example, K48-linked polyubiquitin chains direct the substrate to the 26S proteasome for degradation. In contrast, K63-linked ubiquitination regulates proteasomeindependent functions, including endocytosis and inflammatory immune responses. 3, 4 Other ubiquitin chains, such as K11-linked and K29-linked chains, have been detected in vitro or in vivo. 5, 6 Branched or forked ubiquitin chains result from the attachment of more than two ubiquitin molecules to different Lys residues in a ubiquitin. The functional significance of K29-linked ubiquitin chains or forked ubiquitin chains has not been established so far.
Posttranslational modifications of p53 play critical roles in p53 regulation. In unstressed cells, p53 levels are low because of proteolytic polyubiquitination mediated by redundant ubiquitin signalling. 7 The principal ubiquitin ligase (E3) for p53 degradation is Mdm2, the importance of which is underscored by the genetic evidence that the early embryonic lethality in Mdm2À/À mice can be completely rescued by simultaneous inactivation of p53. [8] [9] [10] Upon DNA damage, activated ATM/ATR kinases result in the phosphorylation of p53, allowing the stabilization of p53. 11 The acetylation of p53 is detectable after DNA damage, which is indispensable for p53 activation. 12, 13 Besides Mdm2, COP1 and Pirh2 ubiquitin ligases are transcriptional targets of p53 that cause p53 degradation, 14, 15 which participate in negative feedback loops with p53 in cells, 7, 16, 17 although genetic studies exclude COP1 and Pirh2 from playing a direct role in regulating p53 turnover. 18, 19 Recently, nonproteolytic ubiquitination of p53 has been reported to regulate p53 function. E4F1, an atypical E3 that stimulates K48-linked oligo-ubiquitination of p53, modulates transcriptional activity without changing the p53 protein level. 20 However, whether K48-linkage-independent polyubiquitination of p53 occurs and plays a role in p53 activation upon DNA damage remains largely unknown.
Genomic instability, a hallmark of cancer, occurs preferentially at specific genomic regions known as common fragile sites (CFSs). CFSs have been known for many years as cancer-associated loci, and defects in DNA damage checkpoint lead to increased expression of CFSs. 21, 22 FATS is a newly identified CFS gene at FRA10F, which is susceptible to deletion in tumors induced by DNA damage. 23 FATS is a transcriptional target of p53 required for regulating DNA damage checkpoints, and FATS deficiency is clinically significant. [23] [24] [25] [26] Here, we demonstrate that FATS stabilizes p53 protein in both unstressed and stressed cells. FATS-mediated stabilization of p53 is associated with nonlinear polyubiquitination of p53, independently of K48-linkage. Furthermore, FATS functions as a novel E3 that assembles ubiquitin chains independently of E2. FATS-mediated polyubiquitination of p53 promotes the activation of p53 in response to DNA damage, leading to robust checkpoint response. RESULTS FATS upregulates p53 by promoting its protein stability in response to DNA damage We first investigated the impact of FATS on p53 protein level. The transfection of a FATS-expressing vector, but not the parental empty vector, increased the expression of p53 protein in FATS-null U2OS cells (Figure 1a ). In addition, the expression of NH2-terminal domain of FATS (FATS-N), whose coding region is susceptible to deletion in tumors induced by DNA-damaging agents, 23, 27 was sufficient to significantly increase p53 protein level in both U2OS (Figure 1a ) and MCF-7 cells (Figure 1b) . Similarly, co-transfection of FATS or FATS-N with p53 also increased p53 protein level in p53-null and FATS-null H1299 cells (Figure 1c) . These results indicate that FATS-mediated upregulation of p53 is a general phenomenon. To determine whether FATS is required for the expression of p53 protein, FATS-shRNA was transfected into U87 cells to knock down endogenous FATS. FATS inhibition caused a remarkable decrease in p53 protein (Figure 1d ). Moreover, FATS-induced p53 was localized in the nucleus (Figure 1e ). However, FATS had no effect on the expression of p53 mRNA (Figures 1f and g ).
As p53 is an unstable protein, we next tested whether FATS might stabilize p53 protein. In the presence of cyclohexmide, an inhibitor of protein synthesis, knockdown of FATS dramatically decreased the protein stability of basal p53 in U87 cells (Figure 2a ), demonstrating that FATS stabilizes p53 protein. Consistently, FATS expression increased the half life of exogenously expressed p53 protein in H1299 cells ( Figure 2b ). As p53 protein is further stabilized after DNA damage and its activation is associated with the post-translational modification of phosphorylation and acetylation, we also investigated the effect of FATS on the accumulation and activation of p53 protein in response to DNA damage. FATS expression not only increased the basal level of p53 protein in U2OS cells but also facilitated p53 accumulation after DNA damage (Figure 2c) . Importantly, the phosphorylation and acetylation of p53 protein in stressed cells were enhanced in FATS-expressing cells compared with that in control cells (Figure 2c ), suggesting that FATS promotes p53 activation in response to DNA damage. Consistently, the expression of FATS-N was sufficient to stabilize p53 under genotoxic stress (Figure 2d ). Knockdown of FATS not only decreased basal level of p53 protein but also impaired p53 accumulation and its activation after DNA damage (Figure 2e ), demonstrating that FATS is required for p53 stabilization and activation in both unstressed and stressed cells.
FATS interacts with p53 and inhibits Mdm2 binding to p53 As protein interaction is involved in regulating p53 polyubiquitination and its protein stability, 2, 7 we tested whether FATS might be a p53-interacting protein. Flag-tagged FATS was transfected into U2OS and MCF-7 cells, respectively. FATS formed an immunocomplex with endogenous p53 in cells, and FATS interacted with p53 through its NH2-terminus (Figures 3a and  b ). In line with these observations, FATS specifically interacted with exogenously expressed p53 in H1299 cells (Figure 3c ), and the protein interaction between endogenous FATS and p53 occurred in U87 cells (Figure 3d ). Furthermore, p53 protein directly interacted with p53 through the NH2-terminal domain of FATS ( Figure 3e ). Using truncated mutants of FATS-N for in vitro binding assay, a fragment consisting of 67 amino-acid residues within FATS-N was defined to be required and sufficient for FATS binding to p53 (Figure 3f ). We further showed that FATS suppressed the formation of p53-Mdm2 complex in vivo (Figure 4a) , and the results of GST pulldown assay indicated that FATS directly inhibited Mdm2 binding to p53 in vitro (Figure 4b ). The effect of FATS-N on p53 induction was compromised after knockdown of Mdm2 expression (Figure 4c ). Thus, FATS-mediated inhibition of Mdm2 binding to p53 is involved in FATS-mediated stabilization of p53.
FATS stimulates non-proteolytic polyubiquitination of p53 Ubiquitination is a central mechanism that modulates p53 function. Given that polyubiquitination of p53, mediated by several E3s including Mdm2, 7 leads to its degradation, we speculated that FATS might stabilize p53 by inhibiting polyubiquitination of p53 protein. To test this hypothesis, U2OS cells were transfected with a His-tagged ubiquitin-expressing vector alone or in combination with FATS and subsequently subjected to in vivo ubiquitination assay. Surprisingly, FATSmediated stabilization of p53 was associated with increased polyubiquitination of p53, even without the treatment of MG132, a proteasome inhibitor (Figure 5a ), indicating that FATS-mediated polyubiquitination of p53 does not result in the degradation of p53 protein. Notably, expression of FATS-N was sufficient to stimulate non-proteolytic polyubiquitination of p53, which was even more pronounced after DNA damage (Figures 5b and c) . The non-proteolytic polyubiquitination of p53 was detected using p53-specific antibodies from different sources, excluding the probability of any artifact. Our observations therefore indicate that FATS-mediated polyubiquitination is positively correlated with the protein stability and activation of p53. To further elucidate the mechanism underlying how FATS stabilizes p53, we examined the effect of FATS on Mdm2-mediated K48-linked polyubiquitination of p53. Overexpression of FATS-N abolished Mdm2-mediated K48-linked polyubiquitination of p53, and FATS-N expression alone did not show any effect on stimulating K48-linked polyubiquitination of p53 (Figure 5d ). Moreover, inhibition of Mdm2 significantly increased FATS-mediated non-proteolytic polyubiquitination of p53 (Figure 5e ). These results were in agreement with the observations that FATS directly inhibited Mdm2 binding to p53 (Figure 4) . Therefore, FATS stabilizes p53 by inhibiting Mdm2-induced degradation of p53 and enhancing Mdm2-independent polyubiquitination of p53.
The NH2-terminal domain of FATS is sufficient to assemble nonlinear ubiquitin chains independently of E2 We next tested whether FATS-N might exhibit E3 activity. In vitro ubiquitination assay was performed in a reaction system containing ATP, purified ubiquitin protein, recombinant E1, GST-tagged FATS-N and UbcH5b, an E2 involved in proteolytic polyubiquitination of p53 in vivo.
17,28 Surprisingly, GST-tagged FATS-N, but not GST alone, exhibited E3 activity in the absence of UbcH5b, rather than in the presence of UbcH5b (Figure 6a ), suggesting that FATS is a novel E3 assembling ubiquitin chains through the E1-E3 cascade in an E2-independent manner. The E3 activity of FATS was confirmed by the observation that FATS-N assembled ubiquitin chains in an ATP-dependent and E2-independent manner (Figure 6b ), indicating the requirement of ATP-dependent activation of ubiquitin by E1 for FATS to exhibit E3 activity. To exclude the possibility that GST-FATS might be contaminated by other E3 ligases, GST-tagged FATS C-terminal fragment (FATS-C) was used for in vitro ubiquitination assay as a negative control. FATS and its response to DNA damage S Yan et al Indeed, FATS-N, but not FATS-C, exhibited E3 activity in the absence of E2. The E3 activity of FATS in vitro was also inhibited in the presence of another E2, UbcH5c (Figure 6c ), demonstrating that FATS is an E2-independent E3 ligase.
To identify FATS-mediated ubiquitin linkage, we performed in vitro ubiquitination assay using Ub-K63R or Ub-K48R, a kind of ubiquitin mutant in which one of the lysine residues of ubiquitin is substituted with arginine, in the presence of E1 and purified FATS-N but in the absence of E2. Indeed, FATS-N assembled ubiquitin chains from Ub-K48R much more efficiently than that from Ub-K63R. Interestingly, FATS-N-catalyzed ubiquitin chains from Ub-K63R were still detectable ( Figure 6d ). These results indicate that other ubiquitin linkages, besides K63-linkage, are involved in E2-independent E3 activity of FATS. To define FATS-mediated ubiquitin linkages, we analyzed in vitro E3 activity of FATS using another kind of ubiquitin mutant, in which only one lysine residue remained in a ubiquitin molecule (Ub-K6-only, Ub-K11-only, Ub-K29-only, Ub-K48-only and Ub-K63-only). We found that FATS-N assembled ubiquitin chains through K63-, K11-and K29-linkage independently of E2 (Figure 6e ), suggesting that FATS-catalyzed ubiquitin linkages have the potential to form branched or forked ubiquitin chains. Notably, purified GST-tagged FATS-N, rather than GST alone, formed complexes with ubiquitin, and the affinity of FATS-N to ubiquitin was remarkably enhanced in the presence of E1 (Figure 6f) . Moreover, such thioester bond formation was abolished by a reducing agent, DTT (Figure 6f ), demonstrating that FATS forms reduction-sensitive thioester complexes with ubiquitin. In line with FATS-catalyzed non-proteolytic polyubiquitination of p53 in vivo ( Figure 5 ), FATS-N exhibited significant E3 activity toward p53 in vitro in an E2-independent manner, in the presence of wild-type ubiquitin but not Ub-K48-only, a ubiquitin mutant containing only lysine-48 without other lysine residues (Figure 6g) Figure 1a) , excluding the possibility that FATS may be an E2 with ubiquitin ligase activity. Given that FATS-N is sufficient to generate non-linear ubiquitin chains without E2, FATS might be a new class of E3s that act as RING/HECT hybrids. 29 To test whether FATS may act as a HECT-type E3 that possesses a conserved catalytic Cys residue, we generated FATS-N mutants (FATS-N-C118G, FATS-N-C202G, FATS-N-C211G and FATS-N-C247G) by site-specific mutagenesis (Supplementary Figures 1c-e) and carried out ubiquitination assays subsequently in the same cell-free system. The E2-independent E3 activities of FATS-N-C118G, FATS-N-C202G and FATS-N-C247G were significantly detected. However, the E3 activity of FATS-N-C211G was undetectable under the same conditions (Figure 6h ), demonstrating that Cys-211 is the catalytic residue of FATS for its E2-independent E3 activity.
FATS-catalyzed polyubiquitination increases p53 transcriptional activity and is required for robust activation of p53 after DNA damage The transcriptional activity of p53 is crucial for determining cellular responses upon p53 activation. We further tested whether FATS might modulate the transcriptional activity of p53. FATS Lysates from U87 cells were immunoprecipitated using a rabbit polyclonal antibody against FATS or a rabbit IgG control, and co-immunoprecipitation of endogenous FATS and p53 was analyzed by immunoblotting using a mouse monoclonal antibody against p53. (e) GST-tagged FATS-N was incubated with in vitro translated p53, and pulled-down proteins were blotted by an antibody against p53. (f ) GST pulldown assay was performed using truncated FATS-N mutants, and their binding activities to p53 were summarized.
significantly increased the luciferase activity derived from pGL2-p21-luc, a luciferase reporter driven by p21 promoter carrying p53-responsive elements, in p53-wild-type MEF cells. However, such an effect was abolished in p53-null MEF cells (Figure 7a ), suggesting that FATS-stimulated p53-dependent transcription of p21. Consistently, FATS-N overexpression significantly increased the level of p21 mRNA in MEF cells carrying wild-type p53 (Figure 7b ), which was correlated with FATS-N-induced enrichment of p53 protein at a p53-responsive element in p21 promoter (Figure 7c ). In agreement with the fact that FATS is a p53 target gene, 24 FATS-N also increased the luciferase activity derived from pGL3-FATS-luc, a luciferase reporter driven by FATS promoter carrying a p53-responsive element (Supplementary Figure 2) , which supported the observation that FATS inhibition impaired p53-dependent induction of FATS protein in p53-wild-type U87 cells after DNA damage (Figure 2e) .
To determine whether FATS-mediated polyubiquitination of p53 may modulate p53 transcriptional activity, we used FATS-N and FATS-N-C211G, a FATS mutant defective in polyubiquitinating p53 in vivo (Figure 7d) , to carry out luciferase assay under the same conditions. Cotransfection of FATS-N and p53 significantly increased p53-dependent luciferase activity of pGL2-p21-luc in p53-null H1299 cells. However, the effect of FATS-N-C211G on stimulating p53-dependent transcriptional activity was remarkably compromised (Figure 7e and Supplementary Figure 2) . Thus, FATSmediated non-proteolytic polyubiquitination of p53 enhances the transcriptional activity of p53, facilitating the p53-dependent effect of cell-cycle arrest (Figures 7f and g ).
We next investigated the impact of the catalytic and noncatalytic functions of FATS on p53 stability and its activation after DNA damage. The E3-defective mutant of FATS, FATS-N-C211G, whose catalytic residue was mutated but not required for p53-binding (Figure 3f and Supplementary Figure 1) , directly bound to p53 with the same binding activity as wild-type FATS-N did (Figure 8a ). We then compared the impacts of Flag-tagged FATS-N and FATS-N-C211G on endogenous p53 under the same conditions in U2OS cells. Although FATS-N-C211G still stabilized p53, its effect on p53 stabilization was weaker than that of FATS-N (Figure 8b) , suggesting that the suppression of Mdm2-binding to p53 and the modification of p53 by FATS-mediated nonproteolytic polyubiquitination are both required for stabilizing p53. Consistently, the stimulating effect of FATS-N-C211G on p53 accumulation after DNA damage was compromised in comparison to that of FATS-N (Figures 8c and d) . Moreover, although FATS-N-C211G still facilitated the phosphorylation and acetylation of p53 in response to DNA damage, its impact on promoting p53 activation was compromised (Figures 8c and d) . Taken together, FATS-catalyzed non-linear polyubiquitination of p53 is required for robust activation of p53 after DNA damage.
DISCUSSION
The functions of ubiquitin signalling in regulating p53 in unstressed cells have been extensively studied. More than a dozen E3s have been identified to regulate the basal level of p53, and the majority of them target p53 for ubiquitination-dependent proteasomal turnover. 7 However, there is emerging evidence that proteasome-independent ubiquitination of p53 is involved in regulating p53. For example, E4F1-mediated oligo-ubiquitination of p53, which has no effect on p53 stability, modulates the transcriptional activity of p53 and induces a p53-dependent growth arrest. 20 By contrast, WWP1, an E3 stimulating non-proteolytic polyubiquitination of p53 through unknown linkages, causes cytoplasmic accumulation of p53 and inhibits its transcriptional activity. 30 Despite the effect of non-proteolytic ubiquitination on p53 transcriptional activity, none of the previously identified non-proteolytic ubiquitination of p53 is enhanced in accompany with p53 accumulation after DNA damage, excluding the involvement of K48-linked ubiquitin chains in p53 activation after DNA damage. In this study, we first show that FATS-catalyzed polyubiquitination of p53 through K63-, K29-and K11-linkages not only leads to the stabilization of basal p53 but also promotes p53 stabilization after DNA damage. Intriguingly, p53 expression is also influenced by Ubc13, an E2 that stabilizes basal p53. However, Ubc13 induces the cytoplasmic localization of p53 and inhibits p53 transcriptional activity. Although K63-linkage is involved in Ubc13-elicited ubiquitination of p53, and Ubc13 attenuates Mdm2-induced polyubiquitination of p53, Ubc13 still causes the inhibition of p53 function. 31 These reports support the notion that K63-linked linear ubiquitination of p53 or inhibition of Mdm2-binding to p53 alone is not sufficient to direct proper function of p53 in response to DNA damage. Herein, we show that FATS not only inhibits Mdm2-binding to p53, but also polyubiquitinates p53 through K63-linkage-involved nonlinear polyubiquitination of p53, leading to significantly higher extent of p53 activation in response to DNA damage. An E3-defective mutant of FATS, possessing an intact domain required for p53-binding (Figures 3f and 8a) , exhibited decreased capacity to promote p53 stabilization and activation (Figure 8 ), indicating the functional importance of FATS-mediated polyubiquitination for p53 activation. Taken together, inhibition of Mdm2 binding to p53 is sufficient to stabilize p53 and promote p53 activation after DNA damage. However, a more robust stabilization and activation of p53 should be achieved under the situation of FATS-mediated K48-independent non-linear polyubiquitination of p53. How K63-linkage-involved non-linear polyubiquitination of p53 results in robust p53 activation after DNA damage remains to be elucidated. The functional linkage between K48-independent non-linear polyubiquitination and p53 activation may add a new regulatory layer into the complexity of p53 regulation. 32 Despite the existence of a positive feedback loop between FATS and p53, the activation of this loop appears transient and tissuespecific. First, more than a dozen of E3s have been identified to FATS and its response to DNA damage S Yan et al cause ubiquitin-dependent degradation of p53, and there are at least three negative feedback loops between E3 and p53 at the cellular level. [14] [15] [16] [17] These redundant mechanisms underlying negative regulation of p53 activation may terminate the positive feedback loop between FATS and p53 soon after its activation. Second, FATS gene is located at a common fragile site, which is one of the genomic hotspots of DNA damage and carcinogenesis. 22 The FATS-p53 feedback loop is therefore susceptible to termination by DNA damage at FATS gene locus. Third, the expression of FATS is not as ubiquitous as that of p53, and its protein level is the highest in reproduction organs in mouse. 24 The physiological significance of this FATS-p53 feedback loop, which may be fertility-related, needs to be further addressed through studies on translational medicine and mouse models.
In canonical E1-E2-E3 cascade, the function of E2 is to facilitate the transfer of activated ubiquitin from E1 to E3. 4, 33 It's unexpected to find that FATS assembles ubiquitin chains independently of E2 in vitro, providing the evidence that E1-E3 cascade exists. FATS possesses a functional domain with both features of HECT-type and RING-type E3s, which may account for the structural basis of its E2-independent E3 activity. FATS might also be regarded as a new class of E3s that act as a RING/HECT hybrid. Notably, the E3 activity of FATS toward p53 in vitro was significantly detected in the absence of E2 through K48-independent linkage, supporting our notion that FATS directly polyubiquitinates p53 through the E1-E3 cascade without causing p53 turnover. The inhibitory effect of E2 on FATS E3 activity in a cell-free system may result from the competition between FATS and E2 for activated ubiquitin from E1. Moreover, we observed that UbcH5b, an E2 involved in Mdm2-mediated degradation of p53, 17 had a stronger impact on inhibiting E2-independent E3 activity of FATS in vitro than did UbcH5c, an E2 involved in both proteolytic and non-proteolytic ubiquitination of p53, 17, 28 suggesting that different E2s may have different capacities to compete with FATS for activated ubiquiitn from E1. Interestingly, the N-terminal domain of FATS binds to ubiquitin even in the absence of E1 and such binding activity is greatly enhanced in the presence of E1. These observations not only provide the strong evidence for E2-independent E3 activity of FATS, but also indicate that FATS protein has a common feature of ubiquitin-binding domains, which are a collection of modular protein domains that non-covalently bind to ubiquitin and include at least sixteen member domains such as UBA, A20 ZnF and Ubc (E2) et al. 34 It has been reported that A20 functions as an E3 and that UbcH5c, an E2 and a class I Ubc, also binds non-covalently to ubiquitin. 35, 36 The E1-independent and E1-stimulated ubiquitin-binding of FATS may confer its intrinsic E2 feature to some extent, which facilitates FATS to exhibit E3 activity in the absence of extrinsic E2. Despite the evidence that the E2-independent E3 activity of FATS toward p53 in vitro is significant, we cannot rule out the possibility that other cellular factors may be involved in FATS-mediated polyubiquitination chain assembly factor required for MDM2-mediated polyubiquitination and degradation of p53, 37 supports the His-Ub-conjugated proteins were purified, and ubiquitinated p53 was detected by western blotting using a p53 antibody (Ab-6). (c) U2OS cells were transfected with Flag-FATS-N for 24 h and subsequently treated with etoposide (25 mM) for the indicated time. His-Ub-conjugated proteins were purified, followed by western blotting using a p53 antibody (FL-393). (d) U2OS cells were transfected with indicated expression vectors for 24 h. Cells were treated with MG132 (20 mM) for 4 h before collecting protein lysates. K48-linked polyubiquitination of p53 was detected by Western blotting using a p53 antibody (Ab-6). (e) U2OS cells were transfected with indicated expression vectors for 24 h. FATS-mediated non-proteolytic polyubiquitination of p53 before and after knockdown of Mdm2 was examined.
possible involvement of ubiquitin chain assembly factors in FATSmediated polyubiquitination of p53 in vivo.
We did not observe p53-mediated apoptotic effect after FATS overexpression in cells under normal conditions, even though FATS also stimulated the transcription of Bax, a p53-regulated pro-apoptotic gene (Supplementary Figure 3) . We have previously showed that FATS also stabilizes p21 independently of ubiquitination. 23 The dual control of p21 by FATS may launch robust checkpoint response that dominates the cellular effect of FATS-mediated p53 activation, which accounts for FATSinduced p53-independent and p53-dependent cell-cycle arrest. FATS protein therefore acts as a potent activator of the p53-p21 pathway. To the best of our knowledge, FATS is the first identified E3 that is capable of assembling ubiquitin chains through E1-E3 cascade. FATS is also the first E3 that forms a positive feedback loop with p53 to regulate p21 and DNA damage checkpoints, further supporting the notion that cancer-associated CFS genes may act as 'built-in' sensors of DNA damage with active role in maintaining genomic stability. Further identifying the type and site of the linked ubiquitin chains on endogenous p53 in the presence of FATS by mass spectrometry and elucidating the precise mechanism by which non-linear ubiquitination regulates p53 may advance our understanding of p53 pathway and facilitate the development of new approaches against cancer.
MATERIALS AND METHODS
Cell culture and transfection FATS-negative cell lines (MCF-7, U2OS, and H1299) and U87 cells (FATS wild-type, p53 wild-type) 24 were obtained from American Type Culture Collection (ATCC). Mouse embryonic fibroblasts (wild-type and p53 À / À ) were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum. Cells were transfected with plasmids using Nucleofector kit (Amaxa, Cologne, Germany) or Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions.
Plasmid and antibody
Flag-FATS plasmid was constructed by in-frame inserting full-length FATS cDNA into p3xFlag-myc-CMV-26 vector (Sigma, Buchs, Switzerland). Flag-FATS-N was generated by in-frame inserting FATS-(1-363) fragment from pcDNA3-FATS(1-363) 23 into the p3xFlag-myc-CMV-26 vector. GST-FATS-N, that is, GST-FATS(1-363), has been reported previously. 20 A DNA fragment coding 223 amino-acid residues of C-terminal FATS was in-frame inserted into pGEX-6p-1 vector (GE Healthcare Life Sciences, Fairfield, CT, USA) to generate GST-FATS-C. The firefly luciferase reporter pGL2-p21-luc and pGL3-FATS-luc were previously described. 24, 38 The Renilla luciferase reporter pRL-TK was obtained from Promega (Fitchburg, WI, USA). Human FATS-shRNA (TG315108) and Mdm2-shRNA (TG311529) were purchased from Origene (Rockville, MD, USA). GST-Mdm2 was a gift from Dr AL Haas (Medical College of Wisconsin, USA). His-Ub-K48 (without other Ks) was kindly provided by Dr Y Cao (Central South University, China). Antibodies were obtained from the following sources: the rabbit polyclonal antibody to p53 (FL-393) from Santa Cruz (Santa Cruz, CA, USA), and mouse monoclonal antibodies to p53 from NeoMarkers (DO-1, Waltham, MA, USA) and Thermo Scientific (Ab-6, Waltham, MA, USA); the phosphor-specific antibody to p53-Ser15, acetyl-specific antibody to p53-lys382 and ubiquitin antibodies from Cell Signaling (Danvers, MA, USA); Mdm2 antibody from BD Biosciences (San Diego, CA, USA), and mouse monoclonal antibody Flag from Sigma. The FATS antibody was previously described. 24 In vitro ubiquitination assay Ubiquitination assays were carried out by adding GST-FATS(1-363) (1 mg), rabbit E1 (40 ng, Calbiochem or Sigma), UbcH5b (100 ng, Calbiochem, Billerica, MA, USA), His-ubiquitin or ubiquitin (2 mg, Boston Biochem, Cambridge, MA, USA) in ubiquitination buffer (50 mM Tris-HCl [pH 7.4], 2 mM ATP, 5 mM MgCl 2 , 2 mM DTT, 30 mM creatine phosphate and 0.05 mg/ ml creatine phosphokinase) to a final volume of 30 ml. The reactions were incubated at 30 1C for 90 min. The reactions were stopped with 2 Â SDS loading buffer, heated to 95 1C for 5 min, and the proteins were fractionated by SDS/PAGE. Ubiquitinated proteins were detected by immunoblotting using a ubiquitin-specific antibody. Ubiquitin mutants (K48R, K63R, K6 only, K11 only, K29 only, K48 only, and K63 only) were obtained from Boston Biochem.
In vivo ubiquitination assay
Cells were transfected with His-tagged ubiquitin alone or in combination with FATS-expressing vectors. Cell lysates were prepared 24 h after transfection and incubated with Ni-NTA beads (Qiagen, Venlo, Netherlands) in binding buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 2 mM imidazole, 1 mM PMSF, 2 mg/ml apoptinin, 2 mM NaF and 1 mM Na 3 VO 4 ). The beads were collected and washed four times with binding buffer.
Site-directed mutagenesis FATS mutants (C202G, C118G, C211G and C247G) were generated by sitedirected mutagenesis, according to the manufacturer's instructions (Stratagene, La Jolla, CA, USA). The primer sequences were listed as follows: C118-U, Dual luciferase assay Cells (5 Â 10 4 ) were transfected with 250 ng of firefly luciferase reporter (pGL2-p21-luc or pGL3-FATS-luc), 20 ng of the transfection control Renilla vector (pRL-TK) and 100 ng of p53-expressing vector in combination with 500 ng of FATS-expressing vector. At 24 h after transfection, cells were lysed in 1x passive lysis buffer (Promega), and reporter activity was measured using the Dual-Luciferase Reporter Assay System (Promega). Each assay was tested in triplicate in three independent experiments.
GST pulldown assay GST pulldown assay was performed as described previously. 39 
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was performed as described previously. 24 The primer sequences for p21 promoter are 5 0 -GAAGGGGG TCCTTCAACTGT-3 0 and 5 0 -TCCT GCTTTGGAGAAGCTGT-3 0 .
RT-PCR
Total RNA was extracted using Trazol (Invitrogen), reverse transcription was carried out using 2 mg of RNA. cDNA was amplified by PCR using primers as follows. p53: forward, 5 0 -CAGGGAGCACTAAGCGAGCACT-3 0 , reverse, 5 0 -TTT ATGGCGGG AGGTAGACTGA-3 0 ; p21: forward, 5 0 -ACGGTGGAACTTTGACT TCG-3 0 , reverse, 5 0 -CAGGGCAGAGGAAGTACTGG-3 0 ; Bax: forward, 5 0 -CTG ACA TGTTTTCTGACGGC-3 0 , reverse, 5 0 -TCAGCCCATCTTCTTCCAGA-3 0 . The mRNA level of GAPDH was detected using primers as described. 23 The FastStart Universal SYBR Green Master (Rox) was purchased from Roche, Basel, Switzerland (cat.4913850001) for quantitative real time PCR. The amplification reaction was carried out and normalized as previously described. 26 
